Use and impact of bevacizumab in patients undergoing liver resection for metastatic colorectal cancer in routine clinical practice.
Edmond Michael Kwan, Belinda Lee, Hui-Li Wong, Margaret Lee, Rachel Wong, Jeremy David Shapiro, Matthew E Burge, Lara Rachel Lipton, Suzanne Kosmider, Peter Gibbs
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2016
698 Background: In metastatic colorectal cancer (mCRC) patients with isolated liver metastases, surgical resection offers the greatest likelihood of cure. Whilst for mCRC patients treated with palliative intent the addition of bevacizumab to the chemotherapy backbone is of proven benefit, whether to use bevacizumab in the resectable or potentially resectable population is a clinical dilemma. Methods: Consecutive patients who underwent resection of liver metastases were identified from a prospective Australian mCRC registry that captures comprehensive data on patient and tumor characteristics (including resectability), treatment and outcome. The use of bevacizumab in this setting was examine..View full abstract